Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
about
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsLong-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisRegulation of brown adipose tissue recruitment, metabolism and thermogenic function by peroxisome proliferator-activated receptor γDrugs for type 2 diabetes: role in the regulation of bone metabolismNuclear receptors in bone physiology and diseasesBone: incretin hormones perceiver or receiver?The alliance of mesenchymal stem cells, bone, and diabetesOn the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles5-Androstene-3β,7β,17β-triol (β-AET) slows thermal injury induced osteopenia in mice: relation to aging and osteoporosisDiabetes, bone and glucose-lowering agents: clinical outcomes.PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.The current role of thiazolidinediones in diabetes management.Calcific aortic valve stenosis: methods, models, and mechanismsRestoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life spanObesity, Type 2 Diabetes and Bone in Adults.Optimal therapy of type 2 diabetes: a controversial challengeThiazolidinediones and bone fractures.Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action.Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitusPeroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.Fractures are increased and bisphosphonate use decreased in individuals with insulin-dependent diabetes: a 10 year cohort studyIs there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.Control of macrophage activation and function by PPARs.Disease burden evaluation of fall-related events in the elderly due to hypoglycemia and other diabetic complications: a clinical review.Cultured human periosteal-derived cells have inducible adipogenic activity and can also differentiate into osteoblasts in a perioxisome proliferator-activated receptor-mediated fashion.Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.Pharmacogenetics of Anti-Diabetes Drugs.The Look AHEAD Trial: bone loss at 4-year follow-up in type 2 diabetes.A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivityFat infiltration of muscle, diabetes, and clinical fracture risk in older adults.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Medication-induced osteoporosis: screening and treatment strategiesAchieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Thiazolidinediones and fractures: evidence from translating research into action for diabetes.Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal studyDifferential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.Fracture risk in diabetic elderly men: the MrOS study.Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylationCellular and molecular effects of thiazolidinediones on bone cells: a review.Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials
P2860
Q22241134-1006EBAF-DA40-472C-ADB0-EC1FF7F87BEFQ24655666-44ED723B-AFD2-4F7E-B28C-91F3B4F169BDQ26745781-4F87B375-9A69-46D9-899F-6B2CAD04E32DQ26775763-0A5CF49C-D7BE-4F43-A4D8-D2EFCAA9F957Q26853017-86504FE2-0349-408A-88A0-86B611CBB95DQ27008949-93BE7698-D23B-4D51-A861-9BA86504A162Q27012497-AC57E036-F85F-4103-8852-686B5117B061Q27697692-D63A9C94-6F49-4527-8BCB-B37B592CE666Q28748762-9E7C683A-C4D6-4A99-AD1D-09B8A855C124Q30234622-D2680088-CB4A-48C7-A662-1BDF29C4D6A3Q30241952-131006ED-7AA2-47BB-8BF5-CF22347192E2Q30250347-979F89F4-EFC4-4B20-9D3F-E0ED739339AAQ30503246-D5CF8605-371C-493F-8500-8214B6819FD8Q30572405-143AB84E-1F10-4C98-A679-7C2111B57E8EQ33571597-56387B18-96CF-4F1B-BE3E-B884AEBF7066Q33577712-D01AD82B-D730-48D4-BD3B-6A0C9DDD59DCQ33603516-0CE6A348-7B0A-4D5F-9C52-C0BBC82CB5D0Q33717450-CE453F25-A679-4035-9208-5A00B41831B9Q33736122-5C5D8E0C-45CA-41DC-9A19-070E260EE64AQ33772312-98BC10D2-022F-479B-B791-172E33C6DF47Q33785248-DC3EF016-BE07-4793-8220-32F08266C6B5Q33960879-3E5A7E86-20F7-41BD-B303-73AA99951844Q33962601-B7AB95FC-5E60-4047-9209-E2093568B711Q34073775-E5743849-2BC4-4D00-AE1D-6E058534E332Q34102038-474EEA4C-B1FE-49C3-B55C-5364AF8BB502Q34161200-A277B436-76B0-47AF-BFCF-BC3456AC4047Q34181995-0B634CF6-6D68-4953-A34D-A686AAFFDEECQ34219386-99A9CEA8-6F75-44CE-97D5-F59D914C0248Q34249161-9814B56B-D204-4EC5-84DE-1CEC9E381FE5Q34262418-D9A2D6A1-6E30-4B53-BE78-A28A9D1E9179Q34315432-8FC4EF28-CD42-4657-BA50-C3E320D244EDQ34389358-FE32D8B4-B997-4D15-B052-BBDD4FCD92F0Q34563587-2403BDB1-0344-48E8-9750-E5541DC4539BQ34630672-C5C7A087-C200-4F09-A0E0-52773487A671Q34636672-CFA36E24-6934-4AE2-B04A-14840EC7D85EQ34888374-637447A2-D4BA-4968-8E75-8998489F07A3Q35130554-3CBA0186-255C-4DEF-9E7C-165C284EFA0EQ35230678-4A2193DB-B7DC-4CE0-902C-069DA9D76250Q35346767-1780983F-2142-4492-90FB-5BA0CB4FB030Q35408148-7D93D2FE-5275-4F6E-B758-EFCA202390F8
P2860
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).
@ast
Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).
@en
Rosiglitazone-associated fract ...... etes Outcome Progression Trial
@nl
type
label
Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).
@ast
Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).
@en
Rosiglitazone-associated fract ...... etes Outcome Progression Trial
@nl
prefLabel
Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).
@ast
Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).
@en
Rosiglitazone-associated fract ...... etes Outcome Progression Trial
@nl
P2093
P50
P356
P1433
P1476
Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).
@en
P2093
Barbara G Kravitz
Diabetes Outcome Progression Trial (ADOPT) Study Group
Giancarlo Viberti
Mark A Heise
R Paul Aftring
Rury R Holman
Steven M Haffner
William H Herman
P304
P356
10.2337/DC07-2270
P407
P577
2008-01-25T00:00:00Z